These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 9737803

  • 1. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K, Heise T, Weyer C, Herrnberger J, Bender R, Hirschberger S, Heinemann L.
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [Abstract] [Full Text] [Related]

  • 2. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I.
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [Abstract] [Full Text] [Related]

  • 3. Time-action profile of inhaled insulin.
    Heinemann L, Traut T, Heise T.
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [Abstract] [Full Text] [Related]

  • 4. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H.
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [Abstract] [Full Text] [Related]

  • 5. Counterregulatory hormone responses and symptoms during hypoglycaemia induced by porcine, human regular insulin, and Lys(B28), Pro(B29) human insulin analogue (insulin Lispro) in healthy male volunteers.
    Jacobs MA, Salobir B, Popp-Snijders C, Ader H, Heine RJ.
    Diabet Med; 1997 Mar; 14(3):248-57. PubMed ID: 9088775
    [Abstract] [Full Text] [Related]

  • 6. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin.
    Heinemann L, Heise T, Wahl LC, Trautmann ME, Ampudia J, Starke AA, Berger M.
    Diabet Med; 1996 Jul; 13(7):625-9. PubMed ID: 8840095
    [Abstract] [Full Text] [Related]

  • 7. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S, Tusek C, Jacobsen LV, Endahl L, Draeger E, Kapitza C, Heise T.
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [Abstract] [Full Text] [Related]

  • 8. Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study.
    Horvath K, Bock G, Regittnig W, Bodenlenz M, Wutte A, Plank J, Magnes C, Sinner F, Fürst-Recktenwald S, Theobald K, Pieber TR.
    Diabetes Obes Metab; 2008 Jun; 10(6):484-91. PubMed ID: 17764465
    [Abstract] [Full Text] [Related]

  • 9. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J.
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [Abstract] [Full Text] [Related]

  • 10. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
    Rave K, de la Peña A, Tibaldi FS, Zhang L, Silverman B, Hausmann M, Heinemann L, Muchmore DB.
    Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
    [Abstract] [Full Text] [Related]

  • 11. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S.
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [Abstract] [Full Text] [Related]

  • 12. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles.
    Rave K, Nosek L, Heinemann L, Gonzales C, Ernest CS, Chien J, Muchmore D.
    Diabet Med; 2004 Jul; 21(7):763-8. PubMed ID: 15209771
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of subcutaneous insulin lispro versus continuous intravenous regular insulin for the treatment of patients with diabetic ketoacidosis.
    Umpierrez GE, Latif K, Stoever J, Cuervo R, Park L, Freire AX, E Kitabchi A.
    Am J Med; 2004 Sep 01; 117(5):291-6. PubMed ID: 15336577
    [Abstract] [Full Text] [Related]

  • 14. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period.
    Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR.
    Diabetes Res Clin Pract; 2008 Feb 01; 79(2):269-75. PubMed ID: 18164094
    [Abstract] [Full Text] [Related]

  • 15. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I, Weiss R, Yegorchikov Y, Bitton G, Nagar R, Pesach B.
    Clin Ther; 2009 May 01; 31(5):980-7. PubMed ID: 19539098
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.
    Heinemann L, Chantelau EA, Starke AA.
    Diabete Metab; 1992 May 01; 18(1):21-4. PubMed ID: 1563532
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T.
    Exp Clin Endocrinol Diabetes; 1997 May 01; 105(3):140-4. PubMed ID: 9228509
    [Abstract] [Full Text] [Related]

  • 18. AIR inhaled insulin versus subcutaneous insulin: pharmacokinetics, glucodynamics, and pulmonary function in asthma.
    Wolzt M, de la Peña A, Berclaz PY, Tibaldi FS, Gates JR, Muchmore DB.
    Diabetes Care; 2008 Apr 01; 31(4):735-40. PubMed ID: 18192544
    [Abstract] [Full Text] [Related]

  • 19. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.
    Diabetes Obes Metab; 2007 May 01; 9(3):290-9. PubMed ID: 17391154
    [Abstract] [Full Text] [Related]

  • 20. The action profile of lispro is not blunted by mixing in the syringe with NPH insulin.
    Joseph SE, Korzon-Burakowska A, Woodworth JR, Evans M, Hopkins D, Janes JM, Amiel SA.
    Diabetes Care; 1998 Dec 01; 21(12):2098-102. PubMed ID: 9839100
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.